266 related articles for article (PubMed ID: 30873384)
1. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors.
Ortiz MV; Roberts SS; Glade Bender J; Shukla N; Wexler LH
Front Oncol; 2019; 9():108. PubMed ID: 30873384
[TBL] [Abstract][Full Text] [Related]
2. Glypican 3 expression in pediatric malignant solid tumors.
Kinoshita Y; Tanaka S; Souzaki R; Miyoshi K; Kohashi K; Oda Y; Nakatsura T; Taguchi T
Eur J Pediatr Surg; 2015 Feb; 25(1):138-44. PubMed ID: 25344940
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases.
Chan ES; Pawel BR; Corao DA; Venneti S; Russo P; Santi M; Sullivan LM
Pediatr Dev Pathol; 2013; 16(4):272-7. PubMed ID: 23530909
[TBL] [Abstract][Full Text] [Related]
4. Expression of glypican 3 (GPC3) in embryonal tumors.
Saikali Z; Sinnett D
Int J Cancer; 2000 Sep; 89(5):418-22. PubMed ID: 11008203
[TBL] [Abstract][Full Text] [Related]
5. Somatic CTNNB1 mutation in hepatoblastoma from a patient with Simpson-Golabi-Behmel syndrome and germline GPC3 mutation.
Kosaki R; Takenouchi T; Takeda N; Kagami M; Nakabayashi K; Hata K; Kosaki K
Am J Med Genet A; 2014 Apr; 164A(4):993-7. PubMed ID: 24459012
[TBL] [Abstract][Full Text] [Related]
6. Glypican 3 overexpression in primary and metastatic Wilms tumors.
Tretiakova M; Zynger DL; Luan C; Andeen NK; Finn LS; Kocherginsky M; Teh BT; Yang XJ
Virchows Arch; 2015 Jan; 466(1):67-76. PubMed ID: 25366870
[TBL] [Abstract][Full Text] [Related]
7. Glypican 3: a novel marker in testicular germ cell tumors.
Zynger DL; Dimov ND; Luan C; Teh BT; Yang XJ
Am J Surg Pathol; 2006 Dec; 30(12):1570-5. PubMed ID: 17122513
[TBL] [Abstract][Full Text] [Related]
8. GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome.
Veugelers M; Vermeesch J; Watanabe K; Yamaguchi Y; Marynen P; David G
Genomics; 1998 Oct; 53(1):1-11. PubMed ID: 9787072
[TBL] [Abstract][Full Text] [Related]
9. Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression.
Kohashi K; Nakatsura T; Kinoshita Y; Yamamoto H; Yamada Y; Tajiri T; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2013 Apr; 44(4):526-33. PubMed ID: 23084579
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Cancer Immunotherapy Targeting Glypican-3.
Shimizu Y; Suzuki T; Yoshikawa T; Endo I; Nakatsura T
Front Oncol; 2019; 9():248. PubMed ID: 31024850
[TBL] [Abstract][Full Text] [Related]
11. The Simpson-Golabi-Behmel gene, GPC3, is not involved in sporadic Wilms tumorigenesis.
Gillan TL; Hughes R; Godbout R; Grundy PE
Am J Med Genet A; 2003 Sep; 122A(1):30-6. PubMed ID: 12949968
[TBL] [Abstract][Full Text] [Related]
12. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.
Zynger DL; Gupta A; Luan C; Chou PM; Yang GY; Yang XJ
Hum Pathol; 2008 Feb; 39(2):224-30. PubMed ID: 17949790
[TBL] [Abstract][Full Text] [Related]
13. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
14. Frequent silencing of the GPC3 gene in ovarian cancer cell lines.
Lin H; Huber R; Schlessinger D; Morin PJ
Cancer Res; 1999 Feb; 59(4):807-10. PubMed ID: 10029067
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 expression in Wilms tumor and hepatoblastoma.
Toretsky JA; Zitomersky NL; Eskenazi AE; Voigt RW; Strauch ED; Sun CC; Huber R; Meltzer SJ; Schlessinger D
J Pediatr Hematol Oncol; 2001 Nov; 23(8):496-9. PubMed ID: 11878776
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene.
Veugelers M; Cat BD; Muyldermans SY; Reekmans G; Delande N; Frints S; Legius E; Fryns JP; Schrander-Stumpel C; Weidle B; Magdalena N; David G
Hum Mol Genet; 2000 May; 9(9):1321-8. PubMed ID: 10814714
[TBL] [Abstract][Full Text] [Related]
17. The loss of glypican-3 induces alterations in Wnt signaling.
Song HH; Shi W; Xiang YY; Filmus J
J Biol Chem; 2005 Jan; 280(3):2116-25. PubMed ID: 15537637
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of a novel intragenic deletion in GPC3 in three cousins with Simpson-Golabi-Behmel syndrome.
Schmidt J; Hollstein R; Kaiser FJ; Gillessen-Kaesbach G
Am J Med Genet A; 2017 May; 173(5):1400-1405. PubMed ID: 28371070
[TBL] [Abstract][Full Text] [Related]
19. GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome.
Li M; Shuman C; Fei YL; Cutiongco E; Bender HA; Stevens C; Wilkins-Haug L; Day-Salvatore D; Yong SL; Geraghty MT; Squire J; Weksberg R
Am J Med Genet; 2001 Aug; 102(2):161-8. PubMed ID: 11477610
[TBL] [Abstract][Full Text] [Related]
20. Discovery and diagnostic value of a novel oncofetal protein: glypican 3.
Wang SK; Zynger DL; Hes O; Yang XJ
Adv Anat Pathol; 2014 Nov; 21(6):450-60. PubMed ID: 25299314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
